Umbilical Cord MSC for Type 2 Diabetes: Ciming Boao Gains Exclusive Lecheng Clearance

Public reports from Boao Lecheng post says Ciming Boao International Hospital received exclusive clearance for “human umbilical cord mesenchymal stem cell therapy for type 2 diabetes,” framed as the only approved clinical-translation pathway of its kind in China for hard-to-treat T2DM. Points below are source claims. Confirm indication, license, and price in writing. Not medical advice.

The post argues diabetes need not mean lifelong drugs only, progressive islet decline, or uncontrolled glucose swings—and positions the Boao Lecheng International Medical Tourism Pilot Zone as offering a new option for China’s 40+ million people with type 2 diabetes.

Limits of conventional care (as stated)

It cites 40+ million T2DM patients in China, trending younger. Oral agents and insulin are framed as mostly symptomatic—“control without repair”—leaving lifelong medication, glucose swings, and complications as the core patient burden.

Lecheng clearance (as stated)

The post presents stem-cell access in Boao as a turning point after years of glucose-control cycles without islet repair.

On 30 December 2025, the Hainan Boao Lecheng Medical Products Administration issued approval 乐医药监〔2025〕113, authorizing Ciming Boao International Hospital exclusively to run clinical translation of “human umbilical cord MSC therapy for type 2 diabetes.”

Marketing language in the post: a “root-cause repair” logic aiming to rebuild islet function, reduce drug dependence, and lower complication risk—treat as source claims only.

Candidate groups listed in the post

1. Confirmed type 2 diabetes, disease duration ≤10 years;
2. On ≥3 glucose-lowering drugs (including insulin) with still-poor control;
3. Fasting C-peptide >0.4 ng/ml (residual islet function);
4. Goal to reduce medication, delay complications, and improve quality of life.

Eligibility requires individual hospital assessment—do not self-match criteria or stop prescribed therapy.

Claimed advantages (source)

The post contrasts “glucose lowering” with MSC “repair” acting on disease pathways:

01 Islet repair: claimed differentiation/regeneration of islet cells and restored endogenous insulin secretion.

02 Insulin resistance: claimed metabolic-pathway modulation and higher insulin sensitivity with less drug dependence.

03 Anti-inflammation / organ protection: claimed reduction of chronic inflammation and less damage to vessels, nerves, and kidneys.

04 Traceable safety: claimed nationally filed human umbilical cord MSCs (filing no. 2025-03-01), GMP production, good biocompatibility, and “no tumorigenesis / no immune rejection”—source statements; verify with hospital and regulators.

The post calls this China’s first MSC technology cleared for T2DM clinical translation under Lecheng “pilot-first” franchised rules. Confirm license validity, indication, and a written estimate before travel.

Ciming Boao International Hospital (as stated)

Described as a core Lecheng hospital with an endocrinology team covering assessment, treatment, and follow-up. Verify team credentials and pathway directly with the hospital.

The Boao Lecheng International Medical Tourism Pilot Zone, approved by the State Council in February 2013, pilots franchised medical care and health management—aiming for “three synchronizations” of technology, equipment, and drugs with international standards.